AbbVie clears 6 percent jump after Apogee deal, shares extend S&P 500 pharma rally

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 11:51.

AbbVie (US00287Y1091) moved firmly higher on the NYSE after announcing a cash acquisition of Apogee Therapeutics valued at about $10.9 billion, adding another late-stage immunology platform to its portfolio as Reuters highlights. Reuters coverage of the Apogee deal The transaction lands in a phase where large-cap U.S. pharma, including Johnson & Johnson and Merck, has shown robust relative performance in the S&P 500 health care segment.

What Reuters reports on the deal

According to Reuters, AbbVie agreed on 22 June 2026 to acquire Apogee Therapeutics for $135 per share in cash, implying an equity value near $10.9 billion and a roughly 37 percent premium to Apogee’s prior close. Reuters deal terms report The company positions the target’s antibody programs, including APG777 for atopic dermatitis, as complementary to its existing immunology blockbusters.

Management underlined in an M&A call that the deal is intended to help offset long-term revenue headwinds from Humira erosion by adding potential first-in-class or best-in-class assets in inflammatory diseases, as summarized by Seeking Alpha. M&A call transcript summary The company expects to fund the transaction with cash and debt and aims for closing in 2026, subject to customary approvals.

How the shares reacted and what analysts say

On 22 June, AbbVie shares climbed about 6.2 percent to around $230 in New York trading, according to GuruFocus, leaving the stock roughly 28 percent higher over the past 12 months and within a 52-week range of about $182 to $245. GuruFocus performance snapshot This places AbbVie among the stronger performers in U.S. large-cap pharma alongside peers such as Eli Lilly and Novo Nordisk’s U.S.-traded shares.

Analyst data compiled by Finviz show that Bank of America upgraded AbbVie from Neutral to Buy on 30 April 2026 with a price target of $234, while Barclays initiated coverage in February with an Overweight rating and a $275 target, underscoring constructive sentiment on the stock’s pipeline and cash generation. Finviz analyst rating overview The shares therefore trade close to some near-term targets but still below the most bullish published objectives.

The product behind the stock

AbbVie generates a significant share of its revenue from immunology therapies such as Skyrizi, a monoclonal antibody indicated for plaque psoriasis and Crohn’s disease among other conditions, which the company highlights as a key growth driver on its website. AbbVie product and pipeline overview Alongside Skyrizi, hematologic oncology drug Imbruvica and aesthetics products like Botox contribute to a diversified portfolio that the Apogee acquisition is meant to further strengthen.

Where the stock trades today

AbbVie shares (US00287Y1091) last closed on 2026-06-22 at around $230.04 on the NYSE, according to TradingKey, implying a market capitalization near $406 billion at that time. TradingKey price and market cap data

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources deemed reliable but cannot be guaranteed.